Accelerated approvals, surrogate end points, and high drug costs are reshaping cancer center formulary decisions, explained panelists at PCOC.
|Articles|April 1, 1998
The American Journal of Managed Care
- April 1998
- Volume 4
- Issue 4
Attitudes and Behavioral Intentions Regarding Managed Care: A Comparison of Academic and Community Physicians
Advertisement
Articles in this issue
over 28 years ago
Cost of Migraine Management: A Pharmacoeconomic Overviewover 28 years ago
A New Gatekeeper for Back Painover 28 years ago
Alzheimer's Disease: Clinical Features and Pharmacologic Managementover 28 years ago
Medicare HMOs: Who Joins and Who Leaves?Advertisement
Related to this article
Most community oncology practices now administer bispecific antibodies in-office, but reimbursement gaps remain a top barrier, a survey finds.
Tammy Lundstrom, MD, JD, discusses the new childhood vaccine order, single-dose MMR access concerns, and the measles resurgence.
Switching MS patients to subcutaneous ocrelizumab cut chair time 82.8% and delivered $514,544 in 3-year value, a UVA analysis finds.
Topical ruxolitinib prescribing in Medicare Part D surged through 2024, but its cost per day runs 16 times higher than generic tacrolimus.
Baseline biopsies separated 16 patients who later developed hepatocellular carcinoma from 32 matched controls a median 6.1 years ahead.
A narrative review finds specialty pharmacies lack a patient-reported outcome measure built for their workflow, despite frequent contact with patients with MS.
Patients with colorectal or ovarian cancer enrolled in a clinical trial have lower pharmacy and medical costs during the 9 months after trial initiation.
Advertisement
Advertisement
Trending on AJMC
1
COVID-19 or Flu? Symptoms Alone Can't Tell: Tammy Lundstrom, MD, JD
2
Perceptions About CGMs Among Primary Care Physicians and Endocrinologists
3
Oncology Patients in Clinical Trials: A Health Care Cost Analysis
4
Nearly a Decade After CAR T, Medicare’s Cell and Gene Therapy Payment Gap Persists
5